Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

被引：50

作者：

Scott, R. ^{[1
]}

Best, J. ^{[1
]}

Forder, P. ^{[1
]}

Taskinen, M-R ^{[1
]}

Simes, J. ^{[1
]}

Barter, P. ^{[1
]}

Keech, A. ^{[1
]}

Barter, P. ^{[1
]}

Best, J. ^{[1
]}

Colman, P. ^{[1
]}

d'Emden, M. ^{[1
]}

Davis, T. ^{[1
]}

Drury, P. ^{[1
]}

Ehnholm, C. ^{[1
]}

Glasziou, P. ^{[1
]}

Hunt, D. ^{[1
]}

Keech, A. ^{[1
]}

Kesaniemi, Y. A. ^{[1
]}

Laakso, M. ^{[1
]}

Scott, R. ^{[1
]}

Simes, R. J. ^{[1
]}

Sullivan, D. ^{[1
]}

Taskinen, M-R ^{[1
]}

Whiting, M. ^{[1
]}

Ansquer, J-C ^{[1
]}

Fraitag, B. ^{[1
]}

Anderson, N. ^{[1
]}

Hankey, G. ^{[1
]}

Hunt, D. ^{[1
]}

Lehto, S. ^{[1
]}

Mann, S. ^{[1
]}

Romo, M. ^{[1
]}

Li, L. P. ^{[1
]}

Hennekens, C. ^{[1
]}

MacMahon, S. ^{[1
]}

Pocock, S. ^{[1
]}

Tonkin, A. ^{[1
]}

Wilhelmsen, L. ^{[1
]}

Forder, P. ^{[1
]}

Akauola, H. ^{[1
]}

Alford, F. ^{[1
]}

Barter, P. ^{[1
]}

Beinart, I. ^{[1
]}

Best, J. ^{[1
]}

Bohra, S. ^{[1
]}

Boyages, S. ^{[1
]}

Colman, P. ^{[1
]}

Connor, H. ^{[1
]}

Darnell, D. ^{[1
]}

Davis, T. ^{[1
]}

机构：

[1] Univ Sydney, NHMRC Clin Trials Ctr, FIELD Study, Sydney, NSW 2006, Australia

来源：

CARDIOVASCULAR DIABETOLOGY | 2005年 / 4卷 / 1期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1186/1475-2840-4-13

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in patients with diabetes mellitus. This article describes the trial's run-in phase and patients' baseline characteristics. Research design and methods: FIELD is a double-blind, placebo-controlled trial in 63 centres in 3 countries evaluating the effects of fenofibrate versus placebo on CHD morbidity and mortality in 9795 patients with type 2 diabetes mellitus. Patients were to have no indication for lipid-lowering therapy on randomization, but could start these or other drugs at any time after randomization. Follow-up in the study was to be for a median duration of not less than 5 years and until 500 major coronary events (fatal coronary heart disease plus nonfatal myocardial infarction) had occurred. Results: About 2100 patients (22%) had some manifestation of cardiovascular disease (CVD) at baseline and thus high risk status. Less than 25% of patients without CVD had a (UKPDS determined) calculated 5-year CHD risk of <5%, but nearly all had a 5-year stroke risk of <10%. Despite this, half of the cohort were obese (BMI > 30), most were men, two-thirds were aged over 60 years, and substantial proportions had NCEP ATP III features of the metabolic syndrome independent of their diabetes, including low HDL (60%), high blood pressure measurement or treatment for hypertension (84%), high waist measurement (68%), and raised triglycerides (52%). After a 6-week run-in period before randomisation with all participants receiving 200 mg comicronized fenofibrate, there were declines in total and LDL cholesterol (10%) and triglycerides (26%) and an increase in HDL cholesterol (6.5%). Conclusion: The study will show the effect of PPAR-alpha agonist action on CHD and other vascular outcomes in patients with type 2 diabetes including substantial numbers with low to moderate CVD risk but with the various components of the metabolic syndrome. The main results of the study will be reported in late 2005.

引用

页数：9

共 50 条

[41] Short-Term and Long-Term Effects of Fenofibrate Combined with Double Phototherapy on Neonatal Jaundice with High Bilirubin
Zhao, Changliang
Niu, Shiping
Geng, Hongli
Yang, Changkun
Li, Binghui
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 128 : 30 - 30
[42] Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance
Okopien, B
Krysiak, R
Herman, ZS
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (05): : 1770 - 1778
[43] Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia
Pruski, Maciej
Krysiak, Robert
Okopien, Boguslaw
DIABETES CARE, 2009, 32 (08) : 1421 - 1424
[44] Effects of long-term fenofibrate treatment on HDL subspecies in type 2 diabetes: FIELD Helsinki Substudy
Hiukka, Anne
Leinonen, Eeva S.
Ehnholm, Christian
Keech, Anthony
Taskinen, Marja-Riitta
DIABETES, 2006, 55 : A201 - A201
[45] Low-molecular weight fluorophores in type 2 diabetes: associations with diabetes complications and effects of fenofibrate in the FIELD study
Chen, D.
Januszewski, A. S.
Scott, R. S.
O'Connell, R. L.
Aryal, N. R.
Sullivan, D. R.
Watts, G. F.
Taskinen, M. -R.
Barter, P. J.
Best, J. D.
Simes, J.
Keech, A. C.
Jenkins, A. J.
DIABETOLOGIA, 2020, 63 (SUPPL 1) : S457 - S457
[46] Effects of long-term fenofibrate treatment on markers of kidney function in type 2 diabetes: FIELD Helsinki substudy
Hiukka, A.
Leinonen, E.
Forsblom, C.
Groop, P.-H.
Taskinen, M.-R.
DIABETOLOGIA, 2007, 50 : S94 - S94
[47] Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes - The FIELD Helsinki substudy
Forsblom, Carol
Hiukka, Anne
Leinonen, Eeva S.
Sundvall, Jouko
Groop, Per-Henrik
Taskinen, Marja-Riitta
DIABETES CARE, 2010, 33 (02) : 215 - 220
[48] Novel Cardiovascular Risk Factor Prediction of Cardiovascular Events in the (Type 2 Diabetes) FIELD Study and Effects of Fenofibrate
Keech, Anthony C.
Alicia, Jenkins
Whiting, Malcolm
Barter, Philip
Sullivan, David R.
Donoghoe, Mark
Januszewski, Andrej
Karschimkus, Connie
Blankenberg, Stefan
Simes, John
Scott, Russell
Laakso, Markku
Taskinen, Marja-Riitta
Best, James D.
CIRCULATION, 2010, 122 (21)
[49] FENOFIBRATE - HYPOLIPEMIC ACTIVITY AND SAFETY IN LONG-TERM TREATMENT - EFFECTS ON HDL, LDL, VLDL AND APOPROTEIN-B IN SHORT-TERM TREATMENT
ROUFFY, J
SAUVANET, JP
CHANU, B
BAKIR, R
GOYLOEPER, J
SAYA, C
PINAROLI, F
NOUVELLE PRESSE MEDICALE, 1980, 9 (49): : 3747 - 3751
[50] Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment The FIELD Study
Ting, Ru-Dee
Keech, Anthony C.
Drury, Paul L.
Donoghoe, Mark W.
Hedley, John
Jenkins, Alicia J.
Davis, Timothy M. E.
Lehto, Seppo
Celermajer, David
Simes, R. John
Rajamani, Kushwin
Stanton, Kim
DIABETES CARE, 2012, 35 (02) : 218 - 225

← 1 2 3 4 5 →